Tian Zhang, MD, and the Oncology Brothers offer comprehensive insights on the overall survival update for KEYNOTE-564 in renal cell carcinoma.
Videos
A review of interim findings from the AMBASSADOR study looking at adjuvant pembrolizumab in patients with muscle-invasive urothelial carcinoma.
Tian Zhang, MD, and the Oncology Brothers discuss the BRCAAway trial, which is investigating abiraterone, olaparib, or the combination in patients with metastatic castration-resistant prostate cancer.
Following ASCO GU 2024, Tian Zhang, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to discuss results from CONTACT-02 investigating cabozantinib plus atezolizumab in metastatic castration-resistant prostate cancer.
Hatem Soliman, MD, discusses what unmet needs still have to be addressed in the HER2-positive breast cancer space.
Regina Barragan-Carrillo, MD, discusses findings from a large population-based study which found there to be significantly higher rates of nephrectomy among patients with renal cell carcinoma who had received prior thymectomy vs the incidence of nephrectomy overall.
Assess whether the initial therapy aligned with standard guidelines based on disease stage.
Provide an overview of the patient's presentation, diagnosis, and initial treatment plan.
Dr Chao provides his insights into the ongoing complexities that clinicians face and shaping a comprehensive understanding of the areas requiring further attention and innovation in cGvHD management.
Federico Albrecht, MD, discusses the challenging case of a 67-year-old heavy smoker who presented with small cell lung cancer.
Gary J. Schiller, MD, concludes with thoughts on the clinical implications of recent data presented at ASH 2023 on the myelodysplastic syndrome treatment landscape.
A hematologist/oncologist discusses a phase 1b/2 study investigating canakinumab in patients with myelodysplastic syndrome.
Virginia Kaklamani, MD, DSc, explains that key unmet needs in HR+/HER2- metastatic breast cancer include overcoming diverse mechanisms of endocrine resistance with genomic profiling and new agents like oral SERDs while managing side effects.
Virginia Kaklamani, MD, DSc, explains that managing adverse events like fatigue, GI toxicity, and musculoskeletal pain in patients with HR+/HER2- metastatic breast cancer using approaches such as exercise, anti-nausea medication, acupuncture, and supplements is key to meeting the dual treatment goals of prolonging life and maintaining quality of life.
Federico Albrecht, MD, discusses Miami Cancer Institute's specific protocol for hospitalized patients with small cell lung cancer.
Following their review of recent data from the 2024 ASCO GI Cancers Symposium, the Oncology Brothers discuss their key takeaways.
Medical oncologists offer comprehensive insights on the role of circulating tumor DNA in the treatment of patients with colorectal cancer.
Clinical insights on the recent data from the NETTER-2 trial looking at Lu-177 Dotatate in patients with advanced gastroenteropancreatic neuroendocrine tumors.
Pamela L. Kunz, MD, and the Oncology Brothers provide insights on the EMERALD-1 trial looking at durvalumab and bevacizumab plus TACE in patients with unresectable, embolization-eligible hepatocellular carcinoma.
Following ASCO GI 2024, Pamela L. Kunz, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss results from the CheckMate 8HW study investigating nivolumab plus ipilimumab in MSI-high/mismatch repair deficient metastatic colorectal cancer.
Francis P. Worden, MD, reviews the progression-free survival data and safety findings from the phase 3 COSMIC-311 study which evaluated treatment with cabozantinib in patients with radioiodine-refractory differentiated thyroid cancer.
Paul Richardson, MD, further discusses the data from the CC-92480-MM-002 trial, and future directions for research of mezigdomide combinations for patients with relapsed/refractory multiple myeloma.
Douglas Tremblay, MD, discusses the factors which influence the decision to recommend cytoreduction for patients with essential thrombocytopenia and polycythemia vera.
Paul Richardson, MD, discusses the safety and efficacy findings from the CC-92480-MM-002 trial of mezigdomide with dexamethasone and daratumumab or elotuzumab in patients with relapsed/refractory multiple myeloma.
Dr. Zeiser and Dr. Chao review ongoing clinical trials in the management of cGvHD – specifically the use of axatilimab and abatacept in SR/D cGvHD.
Experts discuss the treatments for steroid-refractory/dependent chronic Graft vs Host Disease (SR/D cGvHD), focusing on the unique mechanisms and applications of belumosudil and role of ibrutinib.
Drs Safah and Koprivinikar discuss emerging therapies, such as imetelstat and canakinumab, and where they might fit in the treatment paradigm for lower-risk MDS.
Paul Richardson, MD, discusses the baseline characteristics of the patients with relapsed/refractory multiple myeloma enrolled in the CC-92480-MM-002 trial.
Michiel S. Van der Heijden, MD, PhD, discusses background of the phase 3 CheckMate 901 study which evaluated concurrent frontline nivolumab and gemcitabine/cisplatin followed by nivolumab maintenance therapy among patients with urothelial carcinoma.
Paul Richardson, MD, discusses the background and design of the CC-92480-MM-002 trial in multiple myeloma.